Incannex Healthcare Inc
IXHL
查看详细走势图
0.453USD
+0.015+3.43%
交易中 （美东）报价延迟15分钟
157.48M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.43%
5天
+7.07%
1月
+44.01%
6月
+106.71%
今年开始到现在
-78.64%
1年
-73.04%
查看详细走势图
TradingKey Incannex Healthcare Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Incannex Healthcare Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值低估，在药品行业排名129/158位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现很强，但基本面和技术面综合得分较低，很强的走势没有得到基本面和技术面印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Incannex Healthcare Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Incannex Healthcare Inc亮点
亮点风险
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
业绩增长期
公司处于发展阶段，最新年度总收入86.00K美元
估值合理
公司最新PE估值-0.41，处于3年历史合理位
机构加仓
最新机构持股3.21M股，环比增加36.04%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
活跃度增加
近期活跃度增加，过去20天平均换手率5.19
Incannex Healthcare Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Incannex Healthcare Inc简介
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
公司代码IXHL
公司Incannex Healthcare Inc
CEOLatham (Joel)
网址
常见问题
Incannex Healthcare Inc(IXHL)的当前股价是多少？
Incannex Healthcare Inc(IXHL)的当前股价是 0.453。
Incannex Healthcare Inc的股票代码是什么？
Incannex Healthcare Inc的股票代码是IXHL。
Incannex Healthcare Inc股票的52周最高点是多少？
Incannex Healthcare Inc股票的52周最高点是2.250。
Incannex Healthcare Inc股票的52周最低点是多少？
Incannex Healthcare Inc股票的52周最低点是0.080。
Incannex Healthcare Inc的市值是多少？
Incannex Healthcare Inc的市值是157.48M。
Incannex Healthcare Inc的净利润是多少？
Incannex Healthcare Inc的净利润为-46.88M。
现在Incannex Healthcare Inc(IXHL)的股票是买入、持有还是卖出？
根据分析师评级，Incannex Healthcare Inc(IXHL)的总体评级为--，目标价格为--。
Incannex Healthcare Inc(IXHL)股票的每股收益（EPS TTM）是多少
Incannex Healthcare Inc(IXHL)股票的每股收益（EPS TTM）是-1.074。
相关品种
